publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
abbrevi
ae
acut
exacerb
ali
acut
lung
injuri
cmv
cytomegaloviru
ctd
connect
tissu
diseas
dad
diffus
alveolar
damag
ebv
epsteinbarr
viru
hcv
hepat
c
viru
hhv
human
herpesviru
hsv
herp
simplex
viru
iip
idiopath
interstiti
pneumonia
ild
interstiti
lung
diseas
ipf
idiopath
pulmonari
fibrosi
lip
lymphoid
interstiti
pneumonia
nsip
nonspecif
interstiti
pneumonia
pap
pulmonari
alveolar
proteinosi
pcr
polymeras
chain
reaction
pmx
polymyxin
bimmobil
fiber
column
ppfe
pleuroparenchym
fibroelastosi
ttv
torqu
teno
viru
affili
interstiti
lung
diseas
ild
compris
broad
heterogen
spectrum
pulmonari
parenchym
disord
known
unknown
caus
idiopath
ild
includ
idiopath
interstiti
pneumonia
iip
idiopath
pulmonari
fibrosi
ipf
idiopath
nonspecif
interstiti
pneumonia
nsip
acut
interstiti
pneumonia
idiopath
lymphoid
interstiti
pneumonia
lip
cryptogen
organ
pneumonia
ild
also
present
manifest
underli
system
ill
connect
tissu
diseas
ctd
sarcoidosi
also
result
occup
environment
drug
exposur
pneumoconiosi
hypersensit
pneumon
druginduc
ild
parenchym
lung
diseas
infecti
natur
gener
exclud
classif
ild
howev
potenti
role
infecti
agent
develop
certain
ild
unknown
caus
ipf
continu
concern
remain
clarifi
furthermor
appear
like
phenomenon
acut
exacerb
ae
worsen
clinic
cours
fibrot
ild
part
associ
infect
diagnost
evalu
patient
suspect
ild
also
need
consid
infect
sinc
caus
variou
histopatholog
pattern
commonli
associ
ild
includ
nsip
lip
organ
pneumonia
eosinophil
pneumonia
among
other
tabl
particularli
import
sinc
immunosuppress
agent
commonli
use
treatment
ild
moreov
recent
year
sever
studi
examin
role
antimicrobi
therapi
treatment
ild
especi
ipf
includ
set
ae
research
look
role
infect
pathogenesi
ild
trigger
ae
focu
virus
role
bacteria
less
well
studi
recent
microbiolog
molecular
techniqu
use
sequenc
bacteria
identifi
strain
allow
evalu
alter
lung
microbiom
associ
diseas
process
includ
pulmonari
fibrosi
narr
review
explor
relev
infect
develop
ild
trigger
acut
exacerb
phenomenon
diagnosi
ild
pathogenesi
ipf
common
form
ild
larg
unknown
ipf
character
histopatholog
pattern
usual
interstiti
pneumonia
manifest
tempor
geograph
heterogen
pattern
parenchym
fibrosi
mani
expert
theoriz
repeat
episod
alveolar
injuri
predispos
host
dysfunct
heal
mechan
central
develop
progress
ipf
environment
factor
thought
contribut
includ
dust
particul
exposur
aspir
gastric
content
infect
definit
evid
exist
support
causal
role
infect
pathogenesi
ipf
moreov
ae
infecti
trigger
identifi
minor
patient
possibl
due
limit
test
method
set
ipf
ipf
ae
present
evid
support
possibl
associ
infect
necessarili
impli
caus
effect
moreov
mani
studi
present
carri
era
immunosuppress
agent
system
corticosteroid
commonli
use
treatment
ild
thu
data
respect
infect
must
interpret
accordingli
sever
studi
point
toward
associ
virus
ipf
includ
epsteinbarr
viru
ebv
cytomegaloviru
cmv
adenoviru
hepat
c
viru
hcv
theoriz
virus
provid
persist
antigen
stimulu
predispos
host
lead
fibrosi
evid
anim
murin
model
show
infect
gammaherpesviru
induc
fibrosi
exacerb
establish
fibrosi
evidenc
increas
total
lung
collagen
acut
lung
injuri
ali
histopatholog
diffus
alveolar
damag
dad
reduc
lung
function
frequent
identifi
viru
appear
ebv
egan
et
al
show
vivo
ebv
replic
local
pulmonari
epitheli
cell
patient
ipf
vs
control
subject
importantli
patient
evalu
classifi
immunocompet
major
receiv
ipftarget
therapi
time
biopsi
procedur
tang
et
al
attempt
show
associ
chronic
viral
infect
ipf
use
polymeras
chain
reaction
pcr
techniqu
found
one
herpesvirus
frequent
patient
ipf
vs
control
subject
patient
ipf
vs
control
subject
p
virus
includ
cmv
ebv
human
found
herpesvirus
found
frequent
patient
sporad
case
ipf
famili
case
p
support
role
virus
trigger
pathogenesi
ipf
yonemaru
et
al
studi
patient
ild
case
ipf
seven
case
ctdild
case
sarcoidosi
emphysema
case
compar
cmv
ebv
herp
simplex
viru
hsv
adenoviru
parainfluenza
serolog
show
cmv
igg
complement
fixat
ebv
igg
titer
significantli
higher
patient
ipf
ctdild
compar
group
contrast
adenoviru
parainfluenza
titer
demonstr
signific
differ
among
group
interestingli
patient
increas
cmv
igg
complement
fixat
suggest
latent
cmv
infect
may
promin
ild
give
credenc
theori
pathogen
act
chronic
antigen
stimulu
lung
injuri
specul
pathogen
load
requir
trigger
cascad
inflamm
ultim
fibrosi
may
small
test
identifi
test
hypothesi
santo
et
al
use
immunohistochem
analysi
patient
iip
underw
open
lung
biopsi
procedur
cmv
measl
detect
patient
ipf
nsip
histopatholog
dad
kuwano
et
al
studi
presenc
adenoviru
dna
patient
ctdild
ipf
use
molecular
techniqu
identifi
adenoviru
genom
transbronchi
biopsi
specimen
patient
ipf
patient
ctdild
patient
sarcoidosi
adenovir
dna
present
patient
ipf
patient
ctdild
patient
sarcoidosi
patient
receiv
corticosteroid
like
posit
adenoviru
dna
suggest
immun
statu
host
play
signific
role
adenoviru
truli
associ
pathogenesi
ild
trigger
ae
hcv
caus
liver
fibrosi
number
case
report
suggest
possibl
role
develop
ipf
ueda
et
al
studi
patient
ipf
show
posit
serum
antibodi
hcv
vs
control
subject
healthi
volunt
aras
et
al
studi
cohort
patient
hcv
patient
hepat
b
viru
hcv
group
note
cumul
incid
ipf
respect
compar
zero
case
ipf
hepat
b
viru
group
studi
conclud
age
smoke
liver
cirrhosi
enhanc
develop
ipf
hcvposit
patient
howev
number
studi
fail
replic
associ
lack
consist
signal
among
variou
cohort
suggest
hcv
unlik
import
trigger
develop
ipf
bacteria
less
well
studi
realm
ipf
richter
et
al
current
difficult
determin
whether
patient
ipf
suscept
infect
colon
due
abnorm
lung
parenchyma
associ
traction
bronchiectasi
immunosuppress
medic
histor
commonli
use
treatment
ild
whether
bacteria
involv
trigger
ae
pathogenesi
ipf
studi
israel
found
incid
pulmonari
tuberculosi
chronic
ild
mostli
iip
time
higher
gener
popul
corticosteroid
therapi
found
confound
factor
find
thought
relat
increas
suscept
atyp
infect
result
abnorm
lung
parenchyma
rather
trigger
evolut
ild
lung
microbiom
also
area
research
relat
variou
respiratori
condit
molyneaux
maher
analyz
bal
sampl
patient
ipf
use
cultureindepend
metagenom
analysi
found
phylum
firmicut
streptococcu
veillonella
speci
proteobacteria
bacteroidet
commonli
encount
data
demonstr
lower
airway
thought
steril
colon
microbi
commun
possibl
involv
pathogenesi
progress
lung
injuri
ultim
fibrosi
author
abl
show
longitudin
analysi
patient
ipf
serum
bal
sampl
specif
gene
code
antimicrobi
peptid
present
patient
ipf
express
increas
time
support
theori
pathogen
may
provid
chronic
antigen
stimuli
patient
ipf
fungi
even
less
inform
avail
potenti
role
fungi
pathogenesi
ipf
ae
ipf
occas
pneumocysti
jirovecii
detect
factor
associ
acut
deterior
studi
also
suggest
signific
rate
colon
p
jirovecii
occur
patient
ipf
ild
instanc
vidal
et
al
document
colon
rate
p
jirovecii
patient
ipf
infecti
caus
need
consid
diagnost
evalu
patient
suspect
iip
sinc
histopatholog
pattern
lung
injuri
underli
iip
also
seen
pulmonari
infect
tabl
pattern
includ
nsip
organ
pneumonia
dad
lymphoid
lymphocyt
interstiti
pneumonia
lip
pleuroparenchym
fibroelastosi
ppfe
thu
imper
infect
exclud
diagnos
form
iip
nsip
character
histopatholog
vari
degre
interstiti
chronic
inflamm
fibrosi
appear
tempor
homogen
inconspicu
absent
fibroblast
foci
pattern
lung
injuri
encount
variou
clinic
context
diagnosi
idiopath
nsip
requir
exclus
identifi
caus
exampl
nsip
common
form
ild
found
patient
ctd
form
ctdassoci
ild
initi
descript
nsip
katzenstein
fiorelli
postul
form
lung
injuri
may
repres
result
prior
ali
includ
infect
known
nsip
encount
hivposit
patient
without
p
jiroveci
pneumonia
nsip
also
encount
pattern
lung
involv
viral
infect
human
tcell
lymphotrop
viru
type
organ
pneumonia
nonspecif
respons
wide
array
lung
injuri
includ
infect
histopatholog
character
presenc
organ
polypoid
intralumin
plug
granul
tissu
within
alveolar
space
duct
vari
degre
bronchiolar
involv
similar
idiopath
nsip
diagnosi
cryptogen
organ
pneumonia
entail
exclus
potenti
caus
includ
infect
aspir
inhal
injuri
drug
ctd
system
inflammatori
disord
retrospect
studi
case
organ
pneumonia
pattern
confirm
lung
biopsi
specimen
case
relat
pulmonari
infect
organ
pneumonia
pattern
lung
injuri
seen
mani
form
pulmonari
infect
includ
bacteri
viral
fungal
parasit
seem
like
even
case
diagnos
cryptogen
organ
pneumonia
selflimit
clinic
cours
repres
resolv
pulmonari
infect
dad
histopatholog
pattern
underli
acut
form
iipacut
interstiti
pneumoniaand
case
ard
character
histopatholog
presenc
hyalin
membran
along
diffus
alveolar
septal
thicken
septal
edema
interstiti
fibroblast
prolifer
pattern
encount
patient
variou
form
ali
acut
interstiti
pneumonia
hammanrich
syndrom
refer
dad
occur
absenc
identifi
caus
one
studi
look
patient
dad
major
case
thought
potenti
trigger
identifi
studi
consecut
case
dad
confirm
surgic
lung
biopsi
result
case
thought
infect
relat
commonli
viral
pneumonia
idiopath
lip
current
classifi
rare
form
iip
along
idiopath
ppfe
histopatholog
lip
manifest
diffus
infiltr
alveolar
septa
mostli
lymphocyt
vari
number
plasma
cell
idiopath
form
lip
inde
rare
outnumb
case
associ
disord
immunodefici
ctd
autoimmun
disord
similar
nsip
lip
seen
hivposit
patient
also
associ
sever
viral
infect
includ
ebv
human
tcell
lymphotrop
viru
type
ppfe
recent
delin
entiti
character
histopatholog
elastot
fibrosi
involv
pleura
adjac
subpleur
parenchyma
process
predominantli
affect
upper
lobe
contrast
ipf
sever
underli
diseas
process
implic
case
ppfe
includ
infect
eg
mycobacterium
aspergillu
histori
recurr
infect
describ
patient
ppfe
rais
possibl
may
result
infectionrel
lung
injuri
ppfe
also
seen
reject
phenomenon
recipi
allogen
lung
hematopoiet
stem
cell
transplant
drug
occup
exposur
asbesto
aluminum
chemotherapi
radiat
underli
autoimmun
diseas
hypersensit
pneumon
idiopath
ppfe
rare
form
iip
may
associ
genet
predisposit
form
famili
interstiti
pneumonia
sarcoidosi
sarcoidosi
granulomat
inflammatori
disord
unknown
caus
diagnos
combin
chestjournalorg
clinic
radiograph
histopatholog
find
infect
propos
trigger
lead
aberr
inflammatori
cascad
predispos
host
given
lack
histopatholog
specif
diagnos
sarcoidosi
wide
spectrum
clinic
manifest
difficult
identifi
common
caus
divers
disord
mycobacterium
commonli
implic
speci
although
mycobacterium
demonstr
sarcoid
granuloma
cultur
acidfast
stain
immunohistochem
studi
shown
remnant
mycobacteri
cell
wall
within
sarcoid
specimen
addit
pcr
nucleic
acid
test
demonstr
mycobacteri
nucleic
acid
sarcoid
specimen
metaanalysi
found
mycobacteri
dnarna
identifi
sarcoid
tissu
significantli
higher
nonsarcoid
tissu
control
subject
propionibacterium
also
implic
sarcoidosi
cultur
sarcoid
specimen
import
note
p
acn
commens
bacterium
cultur
larg
proport
healthi
control
subject
eishi
et
al
found
propionibacterium
realtim
pcr
patient
sarcoidosi
also
found
speci
control
subject
systemat
review
studi
patient
found
link
sarcoidosi
p
acn
mycobacteria
herpesviru
also
implic
although
virus
known
trigger
granulomat
reaction
variou
pathogen
studi
includ
borrelia
rickettsia
helvetica
chlamydia
pneumonia
ebv
retrovirus
associ
sarcoidosi
studi
support
confirm
theori
variou
antigen
stimul
granulomat
inflamm
predispos
host
microorgan
act
trigger
vari
current
avail
antibiot
target
enzym
encod
microbi
gene
found
present
site
granulomat
inflamm
sarcoid
specimen
random
placebocontrol
trial
patient
chronic
cutan
sarcoidosi
random
receiv
concomit
levofloxacin
ethambutol
azithromycin
rifampin
vs
placebo
week
demonstr
reduc
diamet
sarcoid
skin
lesion
overal
clinic
improv
treatment
arm
regimen
use
patient
chronic
pulmonari
sarcoidosi
encourag
outcom
includ
improv
fvc
function
capac
qualiti
life
group
pursu
regimen
larger
cohort
patient
confirm
find
clinicaltrialsgov
use
antimicrobi
agent
direct
target
enzym
may
innov
treatment
altern
also
evid
sarcoidosi
may
transmiss
bone
marrow
transplant
donor
sarcoidosi
result
granuloma
format
recipi
although
directli
support
infect
support
theori
antigen
stimulu
lead
granuloma
format
whether
sarcoidosi
result
activ
latent
infect
abnorm
respons
remnant
clear
partial
clear
infect
theori
continu
debat
infect
may
act
simpli
stimulu
aggress
inflammatori
reaction
predispos
host
predispos
host
one
type
antigen
stimulu
lead
clinic
manifest
sarcoidosi
less
common
form
ild
role
infect
deserv
mention
acut
eosinophil
pneumonia
gener
thought
acut
respiratori
ill
unknown
caus
recent
year
cigarett
smoke
medic
identifi
incit
agent
subset
patient
acut
eosinophil
pneumonia
also
recogn
acut
eosinophil
pneumonia
infecti
origin
seen
fungal
pneumoniasfor
exampl
coccidioidomycosi
parasit
infect
sinc
corticosteroid
frequent
use
treatment
idiopath
acut
eosinophil
pneumonia
crucial
possibl
infecti
origin
consid
interstiti
pneumonia
autoimmun
featur
recent
describ
entiti
compris
cohort
patient
ild
featur
autoimmun
extrapulmonari
serolog
meet
criteria
establish
ctd
patient
pose
difficult
question
respect
role
immunosuppress
therapi
littl
known
pathogenesi
interstiti
pneumonia
autoimmun
featur
inde
role
infect
patient
popul
pulmonari
alveolar
proteinosi
pap
diffus
lung
diseas
character
alveolar
fill
process
amorph
lipoproteinac
surfactantlik
materi
case
pap
repres
autoimmun
diseas
mediat
develop
antigranulocyt
macrophagecoloni
stimul
factor
neutral
antibodi
antibodi
induc
function
defici
granulocyt
macrophagecoloni
stimul
factor
critic
mediat
surfact
protein
lipid
homeostasi
alveoli
minor
pap
case
consid
secondari
form
caus
exogen
agent
hematolog
disord
nocardiosi
wellrecogn
infect
complic
cours
patient
pap
addit
p
jiroveci
mycobacteria
cmv
also
report
induc
pap
acut
exacerb
ild
natur
cours
patient
ild
fulli
understood
part
depend
type
underli
ild
especi
fibrot
ild
ae
account
signific
morbid
mortal
although
consensu
definit
aeild
exist
gener
accept
criteria
extrapol
ipf
popul
given
similar
present
ae
gener
character
acut
typic
month
worsen
dyspnea
parenchym
infiltr
imag
occur
mani
form
ild
histolog
character
dad
case
episod
import
caus
ildrel
mortal
surviv
patient
ipf
variou
popul
studi
evolv
definit
ae
retrospect
design
major
studi
make
difficult
assess
true
frequenc
sequela
respiratori
worsen
patient
theori
infect
play
role
pathogenesi
underli
diseas
well
trigger
ae
fulli
evalu
data
support
concept
current
literatur
true
incid
ae
definit
unclear
report
rang
per
year
differ
definit
cohort
studi
larg
explain
variat
current
data
deriv
retrospect
studi
clinic
trial
estim
lower
incid
ae
perhap
due
strict
definit
use
inclus
definit
ae
ipf
broaden
recent
expert
recommend
histor
ae
exclud
infect
revers
condit
ie
heart
failur
venou
thromboembol
despit
advanc
diagnost
method
infect
patient
ild
remain
difficult
diagnos
bronchoscopi
although
quit
specif
diagnos
infect
rel
insensit
particularli
context
recent
antibiot
use
given
inabl
definit
rule
infect
practic
defin
ae
exclus
infect
thu
newli
accept
definit
includ
ae
without
identifi
trigger
infect
tabl
major
patient
respiratori
declin
trigger
identifi
progress
underli
ild
remain
like
caus
howev
host
respons
extern
stimulu
may
import
specif
infect
antigen
may
play
role
trigger
fraction
exacerb
addit
histopatholog
find
dad
patient
ae
lead
natur
correl
aliard
caus
ali
histopatholog
dad
numer
also
thought
includ
infect
aspir
toxin
transfus
surgeri
mani
trigger
may
lead
event
indistinguish
idiopath
exacerb
ild
role
bronchoscopi
clinic
decis
made
case
case
basi
ae
may
tenuou
respiratori
statu
bronchoscopi
may
risk
worsen
set
empir
antibiot
therapi
extens
laboratori
investig
look
identifi
trigger
bronchoscopi
specif
look
infect
may
necessari
patient
ae
risk
procedur
popul
weigh
uncertain
yield
make
difficult
recommend
everi
patient
sinc
effect
outcom
remain
unclear
current
evid
also
support
mandat
investig
search
possibl
trigger
ae
eg
specif
blood
work
serolog
test
clinic
judgment
must
use
determin
appropri
exhaust
test
look
revers
trigger
ae
exampl
test
opportunist
pathogen
patient
receiv
immunosuppress
agent
test
endem
pathogen
data
small
retrospect
studi
report
infecti
caus
trigger
ae
patient
nonipf
fibrot
lung
diseas
one
larger
studi
patient
ild
case
ipf
case
nonipf
show
patient
diagnos
infect
set
acut
respiratori
worsen
also
postmortem
studi
examin
issu
one
studi
patient
ipf
underw
autopsi
show
infect
identifi
includ
fungal
bacteri
viral
anoth
studi
found
patient
ae
bronchopneumonia
fungal
cmv
bacteri
identifi
postmortem
diagnos
clinic
studi
highlight
difficulti
diagnos
infect
clinic
set
support
recent
revis
definit
ae
although
infecti
caus
found
patient
ae
identifi
infect
yet
demonstr
affect
outcom
exampl
blivet
et
al
report
six
patient
confirm
treatabl
pathogen
includ
staphylococcu
aureu
streptococcu
pneumonia
influenza
p
jiroveci
outcom
affect
mortal
remain
high
despit
antibiot
target
organ
two
patient
p
jiroveci
identifi
one
patient
condit
improv
antipneumocysti
therapi
patient
best
cohort
noninfecti
revers
caus
respiratori
worsen
pneumothorax
complic
anesthesia
patient
ae
hsv
n
ebv
n
torqu
teno
viru
ttv
n
ttv
significantli
common
patient
ae
ali
compar
stabl
control
subject
overal
presenc
common
respiratori
viru
detect
patient
ae
howev
presenc
ttv
signific
minor
ae
ali
cohort
may
import
area
futur
studi
result
suggest
presenc
ttv
specif
ae
may
associ
ali
gener
konishi
et
al
also
fail
identifi
gene
transcript
profil
would
expect
viral
infect
patient
ipf
patient
ipf
ae
chlamydophila
pneumonia
infect
known
caus
exacerb
asthma
copd
prospect
studi
conduct
investig
possibl
role
c
pneumonia
infect
trigger
ae
ipf
sputum
blood
cultur
acut
convalesc
serolog
test
c
pneumonia
igg
iga
elisa
perform
prospect
patient
period
two
patient
antibodi
respons
suggest
acut
reactiv
infect
suggest
chlamydophila
unlik
trigger
ae
ipf
although
exist
data
support
role
infectionvirus
case
ae
even
major
possibl
virus
trigger
remain
explor
unlik
respiratori
condit
exacerb
truli
acut
event
onset
ae
ild
gener
insidi
possibl
therefor
time
clinic
present
trigger
virus
would
longer
detect
moreov
signific
proport
patient
ae
may
occult
infect
despit
vigor
clinic
workup
also
epidemiolog
support
infecti
caus
ae
come
studi
demonstr
ae
occur
frequent
winter
spring
month
patient
take
immunosuppress
medic
song
et
al
show
studi
patient
ipf
increas
risk
opportunist
infect
possibl
attribut
prior
treatment
chronic
corticosteroid
therapi
immunosuppress
agent
polymorph
mucin
gene
associ
famili
sporad
ipf
essenti
mucos
immun
defens
healthi
individu
mucociliari
escal
constitut
import
innat
pulmonari
defens
mechan
contrast
cystic
fibrosi
impair
mucociliari
clearanc
predispos
ae
mucociliari
dysfunct
peripher
airway
directli
shown
caus
aeild
even
though
recent
studi
implic
mucin
gene
pathogenesi
sever
ild
attempt
implic
specif
pathogen
etiopathogenesi
ae
often
success
associ
shown
ae
specif
organ
accumul
evid
suggest
multiplehit
hypothesi
lead
progress
deterior
lung
function
infect
possibl
contributor
hit
prognost
implic
ae
profound
data
suggest
death
ipf
preced
ae
median
surviv
patient
ipf
experi
ae
approxim
month
research
area
crucial
clarifi
role
infect
respiratori
worseninga
evalu
role
lung
microbiom
chronic
infecti
stimuli
pathogenesi
ild
although
bacteria
less
commonli
implic
pathogenesi
ild
studi
set
ae
well
antimicrobi
trial
expert
would
agre
empir
antibiot
treatment
set
ae
given
potenti
benefit
minim
risk
patient
occult
infect
remain
possibl
efficaci
azithromycin
treat
ipf
studi
prospect
openlabel
studi
patient
ae
receiv
azithromycin
addit
highdos
puls
steroid
therapi
outcom
compar
histor
cohort
treat
fluoroquinolon
agent
n
primari
end
point
mortal
day
significantli
lower
patient
treat
azithromycin
mortal
vs
p
seriou
advers
event
observ
whether
find
attribut
azithromycin
antiinflammatori
effect
antimicrobi
effect
combin
ascertain
studi
remain
area
investig
placebocontrol
studi
evalu
prophylact
use
cotrimoxazol
month
compar
usual
care
patient
fibrot
iip
although
signific
dropout
cotrimoxazol
arm
vs
placebo
arm
post
hoc
analysi
suggest
cotrimoxazol
led
reduct
infect
mortal
ongo
clinic
trial
look
cotrimoxazol
therapi
ipf
clinicaltri
gov
polymyxinbimmobil
fiber
column
pmx
help
remov
endotoxin
use
treatment
endotoxemia
sever
studi
japan
report
improv
oxygen
patient
ali
ard
treat
pmx
given
dad
common
patholog
find
aliard
ae
treatment
target
aliard
may
relev
manag
ae
retrospect
studi
aim
clarifi
patient
ipf
ae
show
signific
improv
pao
fio
ratio
pmx
treatment
howev
improv
oxygen
translat
surviv
benefit
surviv
rate
respect
patient
ipf
ae
remain
low
recent
retrospect
japanes
studi
suggest
surviv
patient
receiv
pmx
may
improv
pmx
current
accept
treatment
aeild
research
may
support
role
infect
antigen
stimulu
set
ae
role
infect
pathogenesi
ild
aeild
remain
unclear
need
explor
current
literatur
suggest
infect
may
play
role
complex
interact
suscept
host
environ
lead
develop
progress
ild
given
overlap
histopatholog
manifest
infect
ild
infecti
caus
alway
consid
patient
suspect
ild
prior
institut
immunosuppress
therapi
moreov
infect
becom
signific
concern
patient
ild
receiv
chronic
immunosuppress
medic
treatment
ild
recent
studi
suggest
potenti
role
antimicrobi
therapi
treatment
ae
well
ild
